Additional Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of Michigan Hospital
    Ann Arbor MI. 48109
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Baylor College of Medicine
    Houston TX. 77030
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Piedmont Pulmonary and Sleep Medicine Buckhead
    Atlanta GA. 30309-1740
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Dr Anil Dhar Professional Medicine Corporation
    Windsor ON. N8X 5A6
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Northwestern Medicine - Northwestern Medicine Glen
    Glenview IL. 60026-8039
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    McGovern Medical School
    Houston TX. 77030-1501
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Kelowna Allergy and Respiratory Health Clinic
    Kelowna BC. V1W 1V3
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of Kansas Medical Center
    Kansas City KS. 66160
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Dynamic Drug Advancement Ltd.
    Ajax ON. L1S 2J5
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine
    Muncie IN. 47303-3432
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Central Florida Pulmonary Group, PA
    Orlando FL. 32803
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Southeastern Research Center
    Winston-Salem NC. 27103-4029
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Hannibal Regional Healthcare System HRMG Hannibal
    Hannibal MO. 63401-6890
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Coastal Pulmonary and Critical Care PLC
    Saint Petersburg FL. 33704-2733
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Renstar Medical Research
    Ocala FL. 34470
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of Alabama at Birmingham
    Birmingham AL. 35233
    View Details
  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    El Paso Pulmonary Association Elligo PPDS
    El Paso TX. 79902-1124
    View Details
  • Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

    Temple University
    Philadelphia PA. 19140
    View Details
  • Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

    University of Iowa Hospitals and Clinics
    Iowa City IA. 52242
    View Details
  • Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

    University of Texas Health Science Center at Houston (UT Health)
    Houston TX. 77030
    View Details